Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery

Summary

Limited/poor weight loss and weight regain are concerns following bariatric surgery, and weight regain may increase the risk for relapse of comorbidities related to obesity. Medications for weight reduction may assist further weight loss, and support weight maintenance, with positive effects on comorbidities. This pilot study will examine the effect of naltrexone/bupropion and lifestyle advice versus lifestyle advice alone for 7 months in patients with a suboptimal weight trajectory (either little weight loss or weight regain) 2 years or later following bariatric surgery.

Timeline

Start

2020-11-01

Primary completion

2022-09-30

Completion

2022-12-31

Outcome

Outcome not reported

Stopped: “Covid-pandemic”

Drugs

Indications